A Study to Assess Safety and Efficacy of KarXT in Adult Patients With Schizophrenia (EMERGENT-1)
A Phase 2, Randomized, Double-blinded Study to Assess the Safety, Tolerability, and Efficacy of KarXT in Hospitalized Adults With DSM-5 Schizophrenia
Sponsor: Karuna Therapeutics
A PHASE2 clinical study on Schizophrenia, this trial is completed. The trial is conducted by Karuna Therapeutics and has accumulated 10 data snapshots since 2018. Psychiatric clinical trials are essential for establishing evidence-based treatment standards.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Nov 2020 — Jan 2021 [monthly]
Completed PHASE2
-
Oct 2020 — Nov 2020 [monthly]
Completed PHASE2
▶ Show 5 earlier versions
-
Mar 2020 — Oct 2020 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Sep 2019 — Mar 2020 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Apr 2019 — Sep 2019 [monthly]
Recruiting PHASE2
-
Dec 2018 — Apr 2019 [monthly]
Recruiting PHASE2
-
Nov 2018 — Dec 2018 [monthly]
Recruiting PHASE2
First recorded
Sep 2018
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Karuna Therapeutics
For direct contact, visit the study record on ClinicalTrials.gov .